Analytical Data
-
基因名
RUVBL2
- Application
-
别名
48KDA TATA box-binding protein-interacting protein Short name: 48KDA TBP-interacting protein 51KDA erythrocyte cytosolic protein Short name: ECP-51 INO80 complex subunit J Repressing pontin 52 Short name: Reptin 52 TIP49b TIP60-associated protein 54-beta Short name: TAP54-beta
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y230
-
表达区间
2-463aa
-
分子量
67 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RUVBL2, a member of the AAA+ ATPase family, has emerged as a significant focus of research due to its involvement in various cellular processes, including chromatin remodeling, transcriptional regulation, and DNA repair. This protein, encoded by the RUVBL2 gene, plays a critical role in the assembly and function of several multi-protein complexes, influencing cellular functions such as cell cycle progression and apoptosis. Dysregulation of RUVBL2 has been implicated in numerous cancers, making it a potential biomarker and therapeutic target. Recent studies have demonstrated that RUVBL2 interacts with key oncogenic pathways, thereby promoting tumorigenesis. The recombinant expression of RUVBL2 allows researchers to investigate its structure, function, and interactions in detail, paving the way for understanding its role in cancer biology and identifying potential strategies for targeted therapies. Furthermore, the production of RUVBL2 as a recombinant protein facilitates the exploration of its mechanistic roles in various biochemical assays, contributing to the development of inhibitors that could disrupt its function in cancer cells. As a result, RUVBL2 represents a promising candidate for further study in the context of both basic cellular research and clinical applications in cancer treatment.
